February 26, 2021
Business News

Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal

SEATTLE–()–Proniras Corporation, a biotechnology company committed to the development of life saving therapeutic products, today announced that the company and its collaborator, Indiana University (IU) School of Medicine, have received a $12.3 million grant from the National Institute on Drug Abuse (NIDA) to support development of the company’s proprietary molecule, tezampanel, as a treatment for opioid withdrawal syndrome. Tezampanel, a novel antagonist of glutamate receptors, is a small molecule parenteral compound that has been evaluated as a potential therapy for acute migraine in more than 400 human subjects and has demonstrated positive results in a variety of preclinical models of seizure disorder….

Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Riassunto: Colicity Inc. annuncia la chiusura dell’offerta pubblica iniziale da 345 milioni di dollari
Western Union Foundation Supports Career & Leadership Pathways for Migrant and Refugee Youth
Samenvatting: Resultaten Q2, FY 2021: Mytheresa zet sterke groei en winstgevendheid voort